Last reviewed · How we verify

NCT06060184: IonGER

Initiative for Clinical Long-read Sequencing

Not yet recruiting NA Last updated 29 September 2023
What this trial tests

NA trial testing Next-Generation Sequencing (NGS) in Genetic Predisposition in 500 participants. Not yet recruiting.

Timeline
1 December 2023
Primary endpoint
1 December 2025
1 December 2026

Quick facts

Lead sponsorUniversity Hospital Tuebingen
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment500
Start date1 December 2023
Primary completion1 December 2025
Estimated completion1 December 2026
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Tuebingen

Who can join

Eligibility, any sex, with Genetic Predisposition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to comprehensively introduce Long-read Genome sequencing (LR-GS) based genetic testing into clinical routine. In order to demonstrate the superiority of untargeted LR-GS over Short-read Genome sequencing (SR-GS) to establish firm genetic diagnoses, the investigators will rely on a multi-center "Translate Nationale Aktionsbündnis für Menschen mit Seltenen Erkrankungen" (Translate National Action Alliance for People with Rare Diseases Germany, TNAMSE) cohort of unsolved patients with neurological, neurodevelopmental, and imprinting disorders that is expectedly enriched for complex genomic variation. Within the framework of genomDE, the investigators will then implement, for the first time, LR-GS in the diagnostic work-up of a prospective cohort of patients with a broad range of clinical indications including rare diseases and cancer predisposition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Genetic Predisposition

Currently open trials in the same condition.

Other University Hospital Tuebingen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06060184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing